Wells Fargo
ADCT icon

Wells Fargo’s ADC Therapeutics ADCT Stock Holding History

Wells Fargo’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
307,144
+44,361
+17% +$129K ﹤0.01% 4893
2026
Q1 		$985K Sell
262,783
-57,265
-18% -$226K ﹤0.01% 3748
2025
Q4 		$1.13M Buy
320,048
+250,547
+360% +$1.02M ﹤0.01% 3871
2025
Q3 		$278K Buy
69,501
+7,060
+11% +$22.3K ﹤0.01% 4728
2025
Q2 		$167K Sell
62,441
-5,336
-8% -$11.2K ﹤0.01% 4871
2025
Q1 		$95.6K Buy
67,777
+25,945
+62% +$44.1K ﹤0.01% 5118
2024
Q4 		$83.2K Buy
41,832
+11,834
+39% +$31K ﹤0.01% 5296
2024
Q3 		$94.5K Buy
29,998
+4,294
+17% +$13.5K ﹤0.01% 5052
2024
Q2 		$81.2K Buy
+25,704
New +$102K ﹤0.01% 5065
2022
Q4 		– Sell
-200
Closed -$1K – 7433
2022
Q3 		$1K Hold
200
– – ﹤0.01% 6252
2022
Q2 		$2K Hold
200
– – ﹤0.01% 6281
2022
Q1 		$3K Hold
200
– – ﹤0.01% 6563
2021
Q4 		$4K Sell
200
-333
-62% -$8.03K ﹤0.01% 6732
2021
Q3 		$14K Sell
533
-267
-33% -$6.84K ﹤0.01% 6082
2021
Q2 		$19K Sell
800
-1,400
-64% -$32.5K ﹤0.01% 5915
2021
Q1 		$54K Buy
+2,200
New +$63.7K ﹤0.01% 5773

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo's ADCT Position: Q2 2026 in Review

Wells Fargo increased its ADC Therapeutics (ADCT) stake by 17% in Q2 2026, buying an estimated $129K and bringing the position to 307,144 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #4893.

Wells Fargo first reported a position in ADCT in Q1 2021 and has held it in 16 quarters since. The position peaked at $1.13M in Q4 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Wells Fargo held 307,144 shares of ADC Therapeutics worth $329K as of Q2 2026.
  • Wells Fargo bought 44,361 ADC Therapeutics shares in Q2 2026, an estimated $129K.
  • ADC Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4893 holding.
  • Wells Fargo first reported a position in ADC Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Wells Fargo's ADC Therapeutics position peaked at $1.13M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.